Company intelligence / Profile preview

Convergent Therapeutics

Cambridge, Massachusetts, United Statesconvergentrx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Convergent Therapeutics has demonstrated efficacy and safety of its lead asset, CONV01‑α (Ac‑225 rosopatamab tetraxetan), in multiple Phase 1/2 trials for prostate cancer. The company recently began a new Phase II trial for this candidate. Its approach leverages targeted delivery of potent alpha radiation to tumor cells while sparing healthy tissue. Additional pipeline assets are at preclinical or early clinical stages targeting other solid tumors.

Therapeutic areas: Oncology
Modalities: Radiolabeled antibodies (radioantibodies)Therapeutic radiopharmaceuticalsMonoclonal antibodies conjugated with alpha emitters (e.g., Actinium‑225)
Industry: Biotech

Drug pipeline

3 assets

CONV01-α

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Convergent Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Convergent Therapeutics.

Explore the full profile